# Aethon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aethon-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.aethontx.com
- Total disclosed funding: $6M
- Latest round: Series A (Dec 16, 2022)
- Investors on record: 2

## About

Based in New York, US, and founded in 2022 by Raj Chopra (CEO), and Paul Da Silva Jardine, Aethon Therapeutics, Inc. operates as a biotechnology company that creates antibodies that are tailored to work with targeted medicines to specifically attack cancer cells that have developed drug resistance. In January 2023, Aethon Therapeutics, Inc. raised USD 30 million in series A funding from Apple Tree Partners and NYU Langone Health System.

Aethon Therapeutics, Inc. is a platform that is aimed at bridging the gap between targeted and immune therapy. The company provides products such as antibodies that are designed to be used in connection with targeted therapies to preferentially kill drug-resistant cancer cells, and provide health professionals with neoantigens by design that combine immunotherapy and targeted therapy to expand the power and promise of both approaches for cancer patients.

## Funding rounds

- Series A, Dec 16, 2022, $6M — Apple Tree Partners, NYU Langone Health System

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A
- NYU Langone Health System — Series A